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Objective: This manuscript assesses association between depressive symptoms and
symptoms from cancer and its treatment during the first 12 weeks of a new oral
oncolytic treatment.
Methods: This secondary analysis used data from a recently completed trial of an
intervention to improve adherence to oral oncolytic treatment and manage symp-
toms. Following the initiation of the new oral oncolytic medication, 272 patients were
interviewed at intake and weeks 4, 8, and 12 to assess depressive symptoms, and
symptoms from cancer and its treatment. Depressive symptoms were measured using
the Center for Epidemiologic Studies‐Depression (CES‐D20). The summed index of 18
cancer‐related and treatment‐related symptoms as well as the number of symptoms
above threshold at intake, weeks 4, 8, and 12 were related to intake and time‐
varying CES‐D20 using linear mixed effects models.
Results: Depressive symptomatology was a significant predictor of cancer‐related
and treatment‐related symptoms at all‐time points, but the strength of this relation-
ship was greatest at the time of oral oncolytic agent initiation and at week 4. The
strength of this relationship was the same for both summed symptom severity index
and the number of symptoms above threshold, and using either intake or time‐varying
CES‐D20.
Conclusion: Introducing strategies to treat and manage symptoms of depression
along with other symptoms might have added benefits among patients who start a
new oral oncolytic treatment and report modest to higher levels of depressive symp-
toms. Assessments for the impact of strategies to lower depressive symptoms can be
taken within the first 4 weeks.
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Depression occurs in up to 60% of people with cancer, with preva-
lence varying based on cancer type and the extent of the disease.1gov. The ClinicalTrials.gov Identifie
wileyonlinelibrary.com/Cancer patients may manifest depression as an ongoing condition, in
response to their disease, or as a side effect of treatment, such as
the neuropsychiatric effect of chemotherapy.2 Many patients suffer
from depressive symptoms that are not sufficiently severe to warrantr is NCT02043184.
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100 DECKER ET AL.a clinical diagnosis of depression3 but may increase clinic visits,
extended hospitalizations,4,5 reduced adherence to treatment,6-8 and
lower quality‐of‐life.6,9-11
The relationship between depression and common symptoms/side
effects has been studied.12 Ciarmalle and Poli13 and Uchitomi and
colleagues14 reported that somatic symptoms such as insomnia and
fatigue may either cause depression or be a result of depression.
Conclusions from this work are plagued by the use of multiple
assessments tools, differing thresholds for identifying depression,15,16
provider beliefs that feelings of depression are normal, and their reluc-
tance to diagnose and treat depression.17 Further, side effects from
treatment and symptoms from other pathologies often overlap,18
thereby clouding further the role of depression in symptom experience
during cancer treatment.
This work extends this knowledge by determining the associations
of depressive symptomatology with symptoms associated with oral
oncolytic therapy within the first 12 weeks of initiation. Most studies
indicate that patient depression is associated with higher levels of
symptom severity, and some studies indicate that depression may
intensify the cancer patient's perception of the symptoms.19 However,
two interrelated issues deserve clarification. First, what is the relation-
ship between patient depressive symptomatology and cancer‐related
symptoms across time: is the relationship stable, strengthened, or
diminished? Second, are reports of summed symptom severity as well
as number of symptoms reported at a 4 or higher on a 10‐point scale
(a standard for a symptom intervention)20 equally sensitive to patients'
reports of depression as assessed at intake only versus assessments of
depression over time? Answers to these questions could inform future
symptom management trials by pointing to the importance of consid-
ering depressive symptoms as a prognostic factor or a time‐varying
explanatory variable for patient's cancer‐related and treatment‐related
symptom experience over time. These questions are addressed in this
secondary analysis of data from baseline and weeks 4, 8, and 12 col-
lected in a National Cancer Institute funded randomized controlled
trial where the aims were to improve adherence to oral oncolytic ther-
apy and to reduce symptom severity.2 | METHODS
2.1 | Study design and sample
This research was approved by the Institutional Review Board at
Michigan State University (IRB# 13‐076 M) and each participating
comprehensive cancer center. Patients were recruited between 2013
and 2017 from six NCI‐designated Comprehensive Cancer Centers
(University of Michigan, Ohio State University, Yale University, Indiana
University, Northwestern University, and University of Pittsburgh).
Inclusion criteria were as follows: 21 years of age or older, Eastern
Cooperative Oncology Group score of 2 or higher or a Karnofsky
score of ≥50, able to read and speak English, had a cellular or land line
telephone, and new prescription of any one of 28 US Food and Drug
Administration (FDA) approved oral oncolytic agents selected accord-
ing to their FDA approval and emerging use in treating prevalent can-
cers (Supplemental Table 1 lists the 28 drugs prescribed to consentedpatients). Patients prescribed preventive and adjuvant medications for
breast cancer such as tamoxifen, raloxifene, and aromatase inhibitors
were excluded.
Two hundred seventy‐two patients newly prescribed one of 28
FDA approved oral oncolytic agents were enrolled, completed the
baseline interview, and randomized 1:1 to either the intervention or
standard care control arm using a minimization algorithm run from
the central study office to ensure concealment. The algorithm bal-
anced trial arms for recruitment location, site of cancer, level of
depressive symptoms, oral agent regimen complexity (continuous vs
intermittent dosing), and concurrent intravenous chemotherapy. Sub-
sequent interview data were collected via telephone at week 4 (trial
midpoint), week 8 (trial endpoint), and week 12 (follow‐up). Inter-
viewers were blinded to trial arm assignment. In addition to the three
follow‐up interviews, both groups received weekly (weeks 2‐8) auto-
mated voice response system calls. These calls were made at pre‐
arranged times and assessed the severity and interference of 18 com-
mon cancer symptoms.
Participants assigned to the experimental arm who rated a symp-
tom at greater than or equal to 4 were referred to the printed Medica-
tion Management and Symptom Management Toolkit (Toolkit)21 sent to
them following randomization. The Toolkit offered evidence‐based
interventions for management of 18 symptoms and specific strategies
for adherence to oral oncolytic treatment.
Patients in the experimental arm received daily reminder calls to
indicate when and how to take their medication and for those drugs
with rest periods, when to stop and resume their medication.
The results of the trial indicated that adherence was high and did
not differ by trial arm, symptom severity was similar at week 4, lower
in the intervention arm at week 8, and no differences at week 12.22
Trial arm assignment was balanced by level of depression controlled
for in this secondary analysis of symptoms and depression.2.2 | Instruments and measures
2.2.1 | Depressive symptoms
The Center for Epidemiologic Studies Depression Scale‐20 (CES‐D20)
was used to evaluate depression at baseline and weeks 4, 8, and 12;
higher scores reflect higher levels of depression.23 Responses to the
20 items were assessed using a 4‐point Likert‐type scale ranging from:
rarely or none of the time; some of the time; most of the time; and
almost all or all of the time. This measure of depressive symptoms in
cancer patients is common in the literature.24,25 The CES‐D20 score
of 16 or greater is a screening cut‐off for clinical depression. However,
a number of different cut‐points have been reported in the litera-
ture23,26 and benchmarked against the Structured Clinical Interview
for Depression.26,27
We considered the distribution of the CES‐D20 scores in the
sample and used the cut‐off of 8 or higher that corresponds with a
T‐score of 49.8; the PROMIS T‐score of 50 is the mean for the United
States general population.28 This score also corresponds to the mean
in large general population samples that were used to validate the
CES‐D20.23 This cut‐off determines how persons above the national
average for depressive symptoms may differ from those below this
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symptom severity.
The impact of patient depressive symptomatology on cancer‐
related symptoms at baseline, 4, 8, and 12 weeks was assessed in
two ways: by considering baseline depressive symptomatology as a
prognostic factor for symptom experience over time; and by consider-
ing time‐varying depressive symptoms as an explanatory variable for
cancer‐related symptoms at each time point.
2.2.2 | Symptom experience
Eighteen cancer‐ and treatment‐related symptoms were assessed,
they are: anxiety; constipation; cough; diarrhea; fatigue; headaches;
joint pain; lack of appetite; mouth sores; nausea or vomiting; numb-
ness or tingling especially hands and feet; pain; redness or peeling in
hands or feet; shortness of breath; skin rash; sleep disturbance; swell-
ing of hands or feet; and weakness. At intake, 4, 8, and 12 weeks
patients were asked if they had experienced each of these symptoms,
those reporting “Yes” to each symptom were then asked to rate its
severity on a 1 to 9 scale with 1 begin barely noticeable, to a 9 being
worst possible. Severity was summarized as (1) summed index ranging
from 0 to 162; and (2) number of symptoms scored at a 4 or higher
(threshold) at each observation.
2.2.3 | Use of antidepressants
Antidepressant therapy was assessed via audit of each patient's med-
ical record which took place at the end of the study. Each patient was
then categorized according to whether or not they had been pre-
scribed an anti‐depressant medication at intake into the trial.
2.2.4 | Demographic data and clinical history
Data on age, sex, ethnicity, education, marital status, income, and
employment status were obtained at baseline. Clinical data on cancer
diagnosis, stage of cancer, medications for comorbidities, cancer treat-
ments, and complications were obtained from the medical record audit
conducted after patients completed the study (week 12) or dropped
out. Oral oncolytic medications newly prescribed for patients were
collapsed into four classes: kinase inhibitors, cytotoxics, sex hormone
inhibitors, and others (Supplemental Table 1).3 | DATA ANALYSES
Distributions of the symptom and CES‐D20 scores were summarized.
Demographic and clinical characteristics of the sample were compared
according to the baseline CES‐D20 level using t‐, chi‐square, or Fish-
er's exact tests as appropriate. To assess the effects of depressive
symptomatology of cancer‐related symptoms, linear mixed effects
(LME) model was fit for four repeated measures of symptom out-
comes, summed severity index, and number of symptoms above
threshold (one at a time). The explanatory variables were weeks 4, 8,
and 12 (entered as a class variable to model potentially nonlinear pat-
terns), trial arm, patient's age and sex, drug category, use of anti‐
depressants, baseline CES‐D20 score category (≤8 versus 8+), andbaseline CES‐D20 score by week interaction. The LME model general-
izes classical analysis of repeated measures and allows for data missing
at random, so that all patients with non‐missing symptom and CES‐
D20 scores at baseline were analyzed. The inclusion of the CES‐D20
level by time interaction was included to evaluate whether the rela-
tionship between depressive symptomatology and cancer‐related
symptoms changes as time progresses. Least‐square means of symp-
tom outcomes according to the levels of the interaction term were
output from the LME models, and differences between them accord-
ing to the levels of baseline CES‐D20 were tested. The LME modeling
was then repeated with time‐varying CES‐D20 as a covariate instead
of fixed baseline CES‐D20.4 | RESULTS
4.1 | Description of sample
Of the 458 patients screened, 272 consented and completed baseline
interviews. Two patients did not complete the CES‐D20 at baseline
and dropped out following baseline interview; thus, this manuscript
is based on N = 270 patients. Table 1 provides a description of the pri-
mary study sample overall and according to CES‐D20 level at baseline.
Patients were mainly Caucasian (89%), equal number of men and
women, mean age was just over 60, and 74% had at least some college
education. Audits indicated that, on average, patients took medica-
tions for 3.5 comorbid conditions. Cancers were mostly advanced
solid tumors, and majority of patients were treated with cytotoxic
agents or targeted kinase inhibitors. Patients averaged 3.26 cancer‐
related symptoms above threshold at baseline, with mean severity
index of 29.09. Both the number of baseline symptoms above thresh-
old, and summed severity index differed significantly according to the
CES‐D20 level at baseline (P < .01, Table 1). Patients with CES‐D20
above 8 at baseline were older (P = .01) and greater proportion
(32%) were on anti‐depressants compared with patients with baseline
CES‐D20 of 8 or lower, where 17% were on anti‐depressants. The
percent of patients with the CES‐D20 above eight declined over time
with 45% at baseline, 35% at week 4, 33% at week 8, and 30% at
week 12. The mean CES‐D20 in this high group was 17.48 (standard
deviation (SD) 7.94) at baseline (Table 1), then 16.72 (SD 8.26) at week
4, 14.58 (SD 5.20) at week 8, and 15.62 (SD 7.04) at week 12.
The strength of association between the CES‐D20 at baseline and
cancer‐related symptoms differed over time; the interaction terms in
the LME models were significant for both outcomes of symptom
severity (F(3, 647) = 8.10, P < .01 for the interaction term) and number
of symptoms above threshold (F(2, 647) = 6.04, P < .01). The LS means
of cancer‐related symptom outcomes according to the baseline CES‐
D20 level (Table 2) indicate while differences in cancer‐related symp-
tom experience according to the level of CES‐D20 were significant at
each time point, both mean difference in severity and number of
symptoms above threshold decreased over time. While the mean
levels of cancer‐related symptom measures did not change over time
among those with baseline CES‐D20 ≤ 8, there was a significant
decrease over time among those with baseline CES‐D20 above 8
(Table 2, Figure 1A,C). When time‐varying CES‐D20 level was used
TABLE 1 Characteristics of the participants at baseline for the entire sample analyzed, and by the baseline CES‐D20 score subgroup
Characteristic
Entire Sample
N = 270
CES‐D < =8 at Baseline
N = 149
CES‐D > 8 at Baseline
N = 121 P‐Value
Sex .62
Male 134 (50%) 75 (51%) 58 (48%)
Female 136 (50%) 73 (49%) 63 (53%)
Race .25
African American 22 (8%) 11 (7%) 11 (9%)
Caucasian 245 (91%) 138 (93%) 107 (88%)
Other/unknown 3 (1%) 0 (0%) 2 (2%)
Ethnicity .18
Hispanic or Latino 5 (2%) 1 (1%) 4 (3%)
Not Hispanic or Latino 265 (98%) 148 (99%) 117 (97%)
Level of education .17
High school or less 70 (26%) 41 (28%) 29 (24%)
Some college or completed college 150 (56%) 76 (51%) 74 (62%)
Graduate or professional degree 49 (18%) 32 (21%) 17 (14%)
On anti‐depressant <.01
No 206 (76%) 124 (83%) 82 (68%)
Yes 64 (24%) 25 (17%) 39 (32%)
Trial arm .90
Experimental 135 (50%) 74 (50%) 61 (50%)
Control 135 (50%) 75 (50%) 60 (50%)
Drug category .09
Cytotoxic agents 93 (34%) 49 (33%) 44 (36%)
Kinase inhibitors 127 (47%) 71 (48%) 56 (46%)
Sex hormone inhibitors 27 (10%) 20 (13%) 7 (6%)
Other 23 (9%) 9 (6%) 14 (12%)
Site of cancer
Breast 57 (21%) 33 (22%) 24 (20%)
Colorectal 41 (15%) 21 (14%) 20 (17%)
GI 17 (6%) 7 (5%) 10 (8%)
Leukemia 16 (6%) 6 (4%) 10 (8%)
Liver 12 (4%) 5 (3%) 7 (6%)
Lung 10 (4%) 7 (5%) 10 (8%)
Lymphoma 3 (1%) 2 (1%) 1(1%)
Melanoma 8 (3%) 4 (3%) 4 (3%)
Myeloma 7 (3%) 1 (1%) 6 (5%)
Pancreatic 25 (9%) 15 (10%) 10 (8%)
Prostate 26 (10%) 19 (13%) 7 (6%)
Renal 24 (9%) 15 (10%) 10 (8%)
Sarcoma 15 (6%) 9 (6%) 6 (5%)
Brain 2(1%) 1 (1%) 1 (1%)
Esophageal 3 (1%) 1 (1%) 2 (2%)
Other 4 (1%) 3 (2%) 1(1%)
Mean (StDev) Mean (StDev) Mean (StDev)
Age 61.38 (12.22) 63.03 (12.17) 59.35 (12.04) .01
Number of comorbid conditions treated with medications 3.39 (1.99) 3.23 (1.89) 3.57 (2.12) .16
Body mass index 29.09 (7.01) 28.88 (6.88) 29.48 (7.17) .49
Number of symptoms at 4 or higher in severity 3.26 (3.17) 2.03 (2.39) 4.75 (3.36) <.01
Summed symptom severity 23.38 (21.80) 14.61 (14.79) 34.18 (24.15) <.01
CES‐D score 9.76 (8.97) 3.49 (2.62) 17.49 (7.94) <.01
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TABLE 2 The least square means (LS) and standard errors (SE) of symptom severity and number of symptoms above threshold by the CES‐D20
score at baseline and time
Time Outcome
CES‐D20 ≤ 8 at Baseline CES‐D20 > 8 at Baseline
Difference (95% CI), P‐ValueLS Mean (SE) LS Mean (SE)
Baseline Symptom severity index 13.37 (1.67) 32.37 (1.81) −19.00 (−23.42, −14.58), <.01
Number of symptoms above threshold 1.81 (0.25) 4.46 (0.27) −2.56 (−3.30, −1.99), <.01
Week 4 Symptom severity index 14.13 (1.75) 30.03 (1.92) −15.90 (−20.63, −11.16), <.01
Number of symptoms above threshold 1.71 (0.26) 3.97 (0.29) −2.26 (−2.96, −1.55), <.01
Week 8 Symptom severity index 12.15 (1.79) 25.25 (2.03) −13.11 (−18.08, −8.12), <.01
Number of symptoms above threshold 1.49 (0.27) 3.43 (0.30) −1.94 (−2.69, −1.20), <.01
Week 12 Symptom severity index 12.74 (1.76) 21.81 (1.96) −9.07 (−13.88, −4.27), <.01
Number of symptoms above threshold 1.59 (0.26) 2.93 (0.29) −1.33 (−2.05, −0.62), <.01
FIGURE 1 Least square means for summed severity and above threshold at baseline and over time by depression scores
TABLE 3 The least square means (LS) and standard errors (SE) of symptom severity and number of symptoms above threshold by time‐varying
CES‐D20 score and time
Time Outcome
CES‐D20 ≤ 8 CES‐D20 > 8
Difference (95% CI), P‐ValueLS Mean (SE) LS Mean (SE)
Baseline Symptom severity index 14.97 (1.53) 31.35 (1.64) −16.38 (−20.08, −12.69), <.01
Number of symptoms above threshold 2.05 (0.23) 4.32 (0.25) −2.27 (−2.82, −1.72), <.01
Week 4 Symptom severity index 15.10 (1.50) 31.53 (1.83) −16.43 (−20.21, −12.66), <.01
Number of symptoms above threshold 1.77 (0.22) 4.32 (0.27) −2.55 (−3.12, −1.99), <.01
Week 8 Symptom severity index 13.53 (1.60) 24.12 (2.08) −10.58 (−15.11, −6.06), <.01
Number of symptoms above threshold 1.73 (0.24) 3.17 (0.31) −1.44 (−2.12, −0.77), <.01
Week 12 Symptom severity index 13.35 (1.64) 22.87 (2.01) −9.53 (−13.60, −5.45), <.01
Number of symptoms above threshold 1.66 (0.22) 3.06 (0.30) −1.40 (−2.01, −0.79), <.01
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were similar (Table 3, Figure 1B,D). Time‐varying CES‐D20 level was
sensitive in pinpointing the time of the decrease (4 weeks) for the
explanatory role of depressive symptomatology on cancer‐related
symptoms. Symptom severity and the number of symptoms above
threshold for patients who scored above 8 on the CES‐D20 at baseline
remained stable for the first 4 weeks, but then decreased during
weeks 4 through 8 and reached a plateau for weeks 8 through 12.
Finally, age, sex, drug category, and use of anti‐depressants were not
predictive of cancer‐related symptom experience in any of the models
over and above the CES‐D20 score.5 | CONCLUSIONS
This investigation describes how levels of depressive symptomatology
at the onset of oral oncolytic treatment and over 12 weeks differenti-
ate patients according to cancer‐related symptoms over time.
A recent review1 indicates the prevalence of depressive disorders
varies between 5% and 60% depending on diagnostic criteria, depres-
sive assessment tools, and type and stage of cancer. The cut‐off of 16
on CES‐D20 has been used to screen for depression,21,23 and in past
studies of this team with patients treated with infusion chemotherapy
for solid tumor cancers, 34% of patients scored at or above 16.29 In a
104 DECKER ET AL.recent study among patients hospitalized for advanced cancer, the
rate of depressive symptoms was 29%.30 In this sample of patients
for whom oral oncolytic treatment often represented the last available
line of treatment, only 23% scored at 16 or higher on the CES‐D20. In
this report, we used a lower cut‐off of 8 on CES‐D20 that
corresponded to being above or below the national mean for depres-
sive symptoms, according to the cross‐walk between the CES‐D20
and the PROMIS Depression measure.28 Reasons for lower CES‐D20
scores in this sample may include a different point in cancer treatment
trajectory compared with previous samples on infusion chemotherapy,
and prescription of anti‐depressants, which were taken by 24% of
patients at the time of initiation of oral oncolytic treatment.
Compared with previous studies with patients on infusion chemo-
therapy, where summed severity was in the mid 30's, the mean
summed index was approximately 23,31 with the same standard devi-
ation of approximately 23 across similar numbers of symptoms (17 to
18). One reason for lower symptom scores could be a period of no
treatment before oral agent initiation.
In this sample, compared with patients who scored 8 or lower on
CES‐D20, those above 8 had significantly more symptoms above
threshold and greater summed symptom severity index at all observa-
tions. However, the magnitude of the difference in symptom experi-
ence according to the CES‐D20 level decreased over time. While the
symptom burden remained low among those with the CES‐D20 of 8
or lower, both summed severity and number of symptoms at 4 of
higher were reduced between the 4 and 8 week observations and
reached a plateau between weeks 8 and 12. What accounts for this
decline among those scoring higher on depressive symptomatology
remains speculative; the supportive impact of the oral treatment, or
relief over continuing to receive treatment all may be explanations.
The subgroup of patients with higher CES‐D20 became smaller begin-
ning with week 4, possibly because concerns about new treatment
were alleviated.32 The decline in the CES‐D20 by week 4 may explain
subsequent decline in symptoms over weeks 4 to 8, but this explana-
tion could only apply to the results of the analysis with fixed baseline
CES‐D20 level as a covariate. Since the same reduction in symptoms
was seen for time‐varying CES‐D20 level, it appears that even a mod-
est reduction in the actual CES‐D20 score, while still remaining over 8,
could be associated with reduction in other symptoms. The mecha-
nisms by which this occurred are not clear. However, the data point
to the value of incorporating interventions focused on depression
directly into symptom self‐management trials. Specifically, addressing
depression near the time of initiation of oral oncolytic agents may
make self‐management of other symptoms more effective.5.1 | Study limitations
Several limitations deserve mentioning. First, an abiding challenge
toward testing the strength and time order of these relationships is
the diversity of depression measures, their applications to different
sites, stages of cancer, and to treatment modalities. Likely symptoms
such as fatigue, pain, and sleep disturbance may contribute to depres-
sive symptoms. Some literature supports the inclusion of somatic
items in depression measures,33,34 but somatic items are intentionallynot included in the PROMIS depression measure.35 One of the key
issues in choosing items for the depression measurement is that symp-
tom attribution is difficult at best and unreliable at worst.36-38 For
example, is fatigue due to cancer, its treatment, comorbid conditions,
or depression?
Second, these data are confined to only the first 12 weeks of
treatment and do not depict the longer trajectory linking the CES‐
D20 and levels of symptoms. Third, results of these analyses point
to associations between depressive and other cancer‐related symp-
toms, and there may or may not be a causal relationship. Future work
should further examine multiple co‐occurring symptoms during this
treatment modality. Finally, these data were drawn from a symptom
management trial that was successful in lowering symptoms at the
8‐week observation compared with the control arm, with no signifi-
cant differences at the 12‐week observation. These observed differ-
ences, in part, were mitigated by the fact the arms of the trial were
balanced according to level of depression at randomization, and trial
arm assignment was controlled for in the present analysis.5.2 | Clinical implications
This work points to the potential value of a cut‐off of 8 on the CES‐D20
to differentiate the course of symptoms among cancer patients under-
going oral oncolytic treatments. These data could inform behavioral
interventions for patients starting oral oncolytic treatment by first
introducing strategies to treat and manage symptoms of depression
and determining if subsequent self‐management approaches toward
other symptoms are more effective when depression is addressed.
Future work might compare strategies that combine management of
depression with other symptoms, with those that focus on depression
alone or other cancer‐related symptoms alone. From such comparisons,
more could be learned about how managing symptoms of depression
may reduce the severity of other symptoms.39 Further, these compari-
sons might indicate how soon and to what degree the severity of other
symptoms may follow a reduction in depressive symptoms.
ACKNOWLEDGEMENTS
This work was supported by the National Cancer Institute
(1R01CA162401‐01A1).
CONFLICT OF INTERESTS
The authors do not have any potential conflicts of interest, including
relevant financial interests, activities, relationships, and affiliations
relevant to the subject of this manuscript.
ORCID
Charles W. Given http://orcid.org/0000-0001-7478-2621
Barbara A. Given http://orcid.org/0000-0002-3971-214XREFERENCES
1. Caruso R, Nanni MG, Riba M, et al. Depressive spectrum disorders in
cancer: prevalence, risk factors and screening for depression: a critical
review. Acta Oncol. 2017;56(2):146‐155.
DECKER ET AL. 1052. Smith HR. Depression in cancer patients: pathogenesis, implications
and treatment (review). Oncol Lett. 2015;9(4):1509‐1514.
3. Ganz PA. Monitoring the physical health of cancer survivors: a
survivorship‐focused medical history. J Clin Oncol.
2006;24(32):5105‐5111.
4. Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants
for the treatment of depression in people with cancer. Cochrane Data-
base Syst Rev. 2015;6. CD011006. doi: https://doi.org/10.1002/
14651858.CD011006.pub2
5. Prieto JM, Blanch J, Atala J, et al. Psychiatric morbidity and impact on
hospital length of stay among hematologic cancer patients receiving
stem‐cell transplantation. J Clin Oncol. 2002;20(7):1907‐1917.
https://doi.org/10.1200/JCO.2002.07.101
6. Arrieta O, Angulo LP, Núñez‐Valencia C, et al. Association of depres-
sion and anxiety on quality of life, treatment adherence, and
prognosis in patients with advanced non‐small cell lung cancer. Ann
Surg Oncol. 2013;20(6):1941‐1948. https://doi.org/10.1245/s10434‐
012‐2793‐5
7. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for
noncompliance with medical treatment: meta‐analysis of the effects of
anxiety and depression on patient adherence. Arch Intern Med.
2000;160(14):2101‐2107.
8. Walker J, Hansen CH, Martin P, et al. Prevalence, associations,
and adequacy of treatment of major depression in patients with cancer:
a cross‐sectional analysis of routinely collected clinical data. Lancet
Psychiatry. 2014;1(5):343‐350. https://doi.org/10.1016/S2215‐
0366(14)70313‐X
9. Chan A, Ng TR, Yap KY. Clinically‐relevant anticancer‐antidepressant
drug interactions. Expert Opin Drug Metab Toxicol. 2012;8(2):173‐199.
https://doi.org/10.1517/17425255.2012.645804
10. Navari RM, Brenner MC, Wilson MN. Treatment of depressive symp-
toms in patients with early stage breast cancer undergoing adjuvant
therapy. Breast Cancer Res Treat. 2008;112(1):197‐201. https://doi.
org/10.1007/s10549‐007‐9841‐z
11. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta‐
analysis. Psychol Med. 2010;40(11):1797‐1810. https://doi.org/
10.1017/S0033291709992285
12. Miaskowski C, Dunn L, Ritchie C, et al. Latent class analysis reveals
distinct subgroups of patients based on symptom occurrence and
demographic and clinical characteristics. J Pain Symptom Manage.
2015;50(1):28‐37.
13. Ciaramella A, Poli P. Assessment of depression among cancer patients:
the role of pain, cancer type and treatment. Psychooncology.
2001;10(2):156‐165. https://doi.org/10.1002/pon.505
14. Uchitomi Y, Mikami I, Nagai K, Nishiwaki Y, Akechi T, Okamura H.
Depression and psychological distress in patients during the year after
curative resection of non‐small‐cell lung cancer. J Clin Oncol.
2003;21(1):69‐71. https://doi.org/10.1200/JCO.2003.12.139
15. Saracino RM, Weinberger MI, Roth AJ, Hurria A, Nelson CJ. Assessing
depression in a geriatric cancer population. Psychooncology.
2017;26(10):1484‐1490. https://doi.org/10.1002/pon.4160
16. Wakefield C, Butow PN, Aaronson NA, Hack TF, Hubert‐Williams NJ,
Jacobsen PB. Patient‐reported depression measures in cancer: a
meta‐review. Lancet Psychiatry. 2015;2(7):635‐647. https://doi.org/
10.1016/S2215‐0366(15)00168‐6
17. Pasquini M, Biondi M. Depression in cancer patients: a critical review.
Clin Pract Epidemiol Ment Health. 2007;3(1):2.
18. Li M, Fitzgerald P, Rodin G. Evidence‐based treatment of depression in
patient with cancer. J Clin Oncol. 2012;30(11):1187‐1196. https://doi.
org/10.1200/JCO.2011.39.7372
19. Hermelink K, Kuchenhoff H, Untch M, et al. Two different sides of
‘chemobrain’: determinates and nondeterminates of self‐perceived
cognitive dysfunction in a prospective, randomized, multicenter study.
Psychooncology. 2010;19(12):1321‐1328. https://doi.org/10.1002/
pon.169520. National Comprehensive Cancer Network. NCCN clinical practice
guidelines in Oncology, Version 2.2016; 2016. Fort Washington, PA:
National Comprehensive Cancer Network; c2018 [Cited 2018 June
25]. https://www.nccn.org/professionals/physician_gls/default.aspx
21. Given BA, Given CW, Majeske C. Medication Management and Symp-
tom Management Toolkit. East Lansing MI: Michigan State University;
2013.
22. Sikorskii A, Given CW, Given BA, et al. An automated intervention did
not improve adherence to oral oncolytic agents while managing symp-
toms: results from a two‐arm randomized controlled trial. J Pain
Symptom Manage. 2018. August Epub before print. https://doi.org/
10.1016/j.jpainsymman.2018.07.021
23. Radloff LS. The CES‐D20 Scale: a self‐report depression scale
for research in the general population. Appl Psychol Measur.
1977;1(3):385‐401.
24. Carleton RN, Thibodeau MA, Teale MJ, et al. The center for epidemio-
logic studies depression scale: a review with a theoretical and empirical
examination of item content and factor structure. PLoS One. 2013;8(3):
e58067. https://doi.org/10.1371/journal.pone.0058067
25. Segrin C, Badger T, Dorros SM, Meek P, Lopez AM. Interdependent
anxiety and psychological distress in women with breast cancer and
their partners. Psychooncology. 2007;16(7):634‐643.
26. Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression
in the general population with the Center for Epidemiologic
Studies Depression (CES‐D20): a systematic review with meta‐
analysis. PLoS One. 2016;11(5):e0155431. https://doi.org/10.1371/
journal.pone.0155431
27. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Inter-
view for DSM‐IV‐TR Axis I Disorders, Research Version, Non‐Patient
Edition. Biometric Research Department, New York State Psychiatric
Institute; 2002.
28. PROsetta Stone Linking Tables. [website]. Illinois: David Cella, Ph.D.,
Department of Medical Social Sciences at the Feinberg School of Med-
icine, Northwestern University [Cited 2018 June 25]. http://www.
prosettastone.org/LinkingTables1/Pages/default.aspx
29. Given B, Given C, Sikorskii A, et al. Establishing mild, moderate and
severe scores for cancer related symptoms: how consistent and clini-
cally meaningful are interference based severity cut points? J Pain
Symptom Manage. 2008;35(2):126‐135.
30. Nipp RD, El‐Jawahri A, Moran SM, et al. The relationship
between physical and psychological symptoms and health care
utilization in hospitalized patients with advanced cancer. Cancer.
2017;123(23):4720‐4727. https://doi.org/10.1002/cncr.30912.
31. Sikorskii A, Given C, Given B, et al. Symptom management for cancer
patients: a trial comparing two multimodal interventions. J Pain Symp-
tom Manage. 2007;34(3):253‐264.
32. Sikorskii A, Given C, Given B, et al. Do treatment patterns alter beliefs
cancer patients hold regarding oral oncolytic agents? Psychooncology.
2018;27(3):1005‐1012. https://doi.org/10.1002/pon.4606
33. Clover K, Lambert SD, Oldmeadow C, et al. PROMIS depression mea-
sures perform similarly to legacy measures relative to a structured
diagnostic interview for depression in cancer patients. Qual Life Res.
2018;27(5):1357‐1367. https://doi.org/10.1007/s11136‐018‐1803‐x
34. van Wilgen CP, Dijkstra PU, Stewart RE, Ranchor AV, Roodenburg JL.
Measuring somatic symptoms with the CES‐D20 to assess depression
in cancer patients after treatment: comparison among patients with
oral/oropharyngeal, gynecological, colorectal, and breast cancer. Psy-
chosomatics. 2006;47(6):465‐470.
35. Health measures [homepage on the internet]. Illinois: Northwestern
University [Cited 2018 June 25]. Healthmeasures.net
36. Cleeland CS, Sloan JA, Cella D, et al. CPRO (assessing the symptoms of
cancer using patient‐reported outcomes) multisymptom task force.
Recommendations for including multiple symptoms as endpoints in
cancer clinical trials: a report from the ASCPRO (assessing the symp-
toms of cancer using patient‐reported outcomes) multisymptom task
106 DECKER ET AL.force. Cancer. 2013;119(2):411‐420. https://doi.org/10.1002/
cncr.27744
37. Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer:
evidence for a core set of cancer‐related and treatment‐related
symptoms from the Eastern Cooperative Oncology Group
Symptom Outcomes and Practice Patterns study. Cancer.
2013;119(24):4333‐4340. https://doi.org/10.1002/cncr.28376
38. Hillman SL, Mandrekar SJ, Bot B, et al. Evaluation of the value of attri-
bution in the interpretation of adverse event data: a North Central
Cancer Treatment Group and American College of Surgeons Oncology
Group investigation. J Clin Oncol. 2010;28(18):3002‐3007. https://doi.
org/10.1200/JCO.2009.27.4282
39. Voils CI, King HA, Maciejewski ML, Allen KD, Yancy WS Jr, Shaffer JA.
Approaches for informing optimal dose of behavioral interventions.
Ann Behav Med. 2014;48(3):392‐401. https://doi.org/10.1007/
s12160‐014‐9618‐7SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
How to cite this article: Decker V, Sikorskii A, Given CW,
Given BA, Vachon E, Krauss JC. Effects of depressive symp-
tomatology on cancer‐related symptoms during oral oncolytic
treatment. Psycho‐Oncology. 2019;28:99–106. https://doi.
org/10.1002/pon.4916
